ABL1 and mixed phenotype acute leukemia: After the diagnosis of MPAL with atypical e13a3 BCR::ABL1 transcripts, the patient received a combination therapy of VCD (bortezomib, cyclophosphamide, dexamethasone), venetoclax, and dasatinib to treat the Ph + MPAL.